SUPERNUS PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Deferred Income Tax Expense (Benefit) of -$11.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was -$16.95M.
- SUPERNUS PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $5.92M.
- SUPERNUS PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $19.00M.
- SUPERNUS PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$2.65M.
- SUPERNUS PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2025 was $5.21M.
- SUPERNUS PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2024 was -$20.14M.
- SUPERNUS PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2023 was -$25.71M.
- SUPERNUS PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2022 was -$26.32M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$11.03M 10-Q · filed 2026-08-03 | $7.97M derived: sum of 3 quarters · filed 2026-08-03 | $5.33M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $5.92M 10-Q · filed 2026-05-05 | $24.92M derived: sum of 2 quarters · filed 2026-05-05 | $22.27M derived: sum of 3 quarters · filed 2026-05-05 | $15.11M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $16.36M derived: sum of 2 quarters · filed 2026-03-02 | $9.20M derived: sum of 3 quarters · filed 2026-08-03 | $5.21M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$9.81M derived: sum of 2 quarters · filed 2026-08-03 | -$13.80M 10-Q · filed 2025-11-06 | -$13.87M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$7.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$11.15M 10-Q · filed 2026-08-03 | -$11.22M derived: sum of 3 quarters · filed 2026-08-03 | -$17.69M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$3.99M 10-Q · filed 2026-05-05 | -$4.06M derived: sum of 2 quarters · filed 2026-05-05 | -$10.53M derived: sum of 3 quarters · filed 2026-05-05 | -$18.64M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$6.54M derived: sum of 2 quarters · filed 2026-03-02 | -$14.65M derived: sum of 3 quarters · filed 2026-03-02 | -$20.14M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$6.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$14.58M derived: sum of 2 quarters · filed 2025-11-06 | -$20.06M 10-Q · filed 2025-11-06 | -$30.52M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$8.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$13.60M 10-Q · filed 2025-08-05 | -$24.06M derived: sum of 3 quarters · filed 2026-03-02 | -$33.32M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$5.48M 10-Q · filed 2025-05-06 | -$15.94M derived: sum of 2 quarters · filed 2026-03-02 | -$25.21M derived: sum of 3 quarters · filed 2026-03-02 | -$30.76M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$19.73M derived: sum of 2 quarters · filed 2026-03-02 | -$25.28M derived: sum of 3 quarters · filed 2026-03-02 | -$25.71M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$9.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$14.82M derived: sum of 2 quarters · filed 2024-11-04 | -$15.26M 10-Q · filed 2024-11-04 | -$23.02M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$5.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$5.99M 10-Q · filed 2024-08-06 | -$13.75M derived: sum of 3 quarters · filed 2025-02-25 | -$16.26M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$435.00K 10-Q · filed 2024-05-08 | -$8.20M derived: sum of 2 quarters · filed 2025-02-25 | -$10.70M derived: sum of 3 quarters · filed 2025-02-25 | -$13.75M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$10.27M derived: sum of 2 quarters · filed 2025-02-25 | -$13.31M derived: sum of 3 quarters · filed 2025-02-25 | -$26.32M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$5.55M derived: sum of 2 quarters · filed 2023-11-08 | -$18.56M 10-Q · filed 2023-11-08 | -$23.08M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$16.06M 10-Q · filed 2023-08-08 | -$20.57M derived: sum of 3 quarters · filed 2023-08-08 | -$19.00M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$13.01M 10-Q · filed 2023-05-09 | -$17.53M derived: sum of 2 quarters · filed 2023-05-09 | -$15.96M derived: sum of 3 quarters · filed 2023-05-09 | -$15.44M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$2.95M derived: sum of 2 quarters · filed 2023-03-09 | -$2.43M derived: sum of 3 quarters · filed 2023-03-09 | -$4.99M 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.09M derived: sum of 2 quarters · filed 2022-11-09 | -$479.00K 10-Q · filed 2022-11-09 | $369.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $519.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$2.05M 10-Q · filed 2022-08-08 | -$1.20M derived: sum of 3 quarters · filed 2023-03-09 | $1.58M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | -$2.56M 10-Q · filed 2022-05-12 | -$1.72M derived: sum of 2 quarters · filed 2023-03-09 | $1.06M derived: sum of 3 quarters · filed 2023-03-09 | -$2.54M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $848.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.63M derived: sum of 2 quarters · filed 2023-03-09 | $30.00K derived: sum of 3 quarters · filed 2023-03-09 | $568.00K 10-K · filed 2023-03-09 |
| 2020-09-30 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$818.00K derived: sum of 2 quarters · filed 2021-11-05 | -$280.00K 10-Q · filed 2021-11-05 | -$4.42M derived: sum of 4 quarters · filed 2022-04-13 |
| 2020-06-30 | -$3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$3.06M 10-Q · filed 2021-08-06 | -$7.21M derived: sum of 3 quarters · filed 2022-04-13 | -$9.76M derived: sum of 4 quarters · filed 2022-04-13 |
| 2020-03-31 | $538.00K 10-Q · filed 2021-05-07 | -$3.60M derived: sum of 2 quarters · filed 2022-04-13 | -$6.16M derived: sum of 3 quarters · filed 2022-04-13 | -$5.57M derived: sum of 4 quarters · filed 2022-04-13 |
| 2019-12-31 | -$4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-13 | -$6.69M derived: sum of 2 quarters · filed 2022-04-13 | -$6.11M derived: sum of 3 quarters · filed 2022-04-13 | -$5.83M 10-K · filed 2022-04-13 |
| 2019-09-30 | -$2.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$1.97M derived: sum of 2 quarters · filed 2020-11-06 | -$1.69M 10-Q · filed 2020-11-06 | $377.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $582.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $861.00K 10-Q · filed 2020-08-17 | $2.93M derived: sum of 3 quarters · filed 2021-03-08 | -$2.91M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $279.00K 10-Q · filed 2020-05-15 | $2.35M derived: sum of 2 quarters · filed 2021-03-08 | -$3.49M derived: sum of 3 quarters · filed 2021-03-08 | -$2.77M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | -$3.77M derived: sum of 2 quarters · filed 2021-03-08 | -$3.05M derived: sum of 3 quarters · filed 2021-03-08 | -$4.17M 10-K · filed 2021-03-08 |
| 2018-09-30 | -$5.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$5.11M derived: sum of 2 quarters · filed 2019-11-08 | -$6.23M 10-Q · filed 2019-11-08 | $1.68M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $725.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$395.00K 10-Q · filed 2019-08-09 | $7.51M derived: sum of 3 quarters · filed 2020-02-28 | $9.16M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | -$1.12M 10-Q · filed 2019-05-10 | $6.79M derived: sum of 2 quarters · filed 2020-02-28 | $8.43M derived: sum of 3 quarters · filed 2020-02-28 | $15.85M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $7.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $9.55M derived: sum of 2 quarters · filed 2020-02-28 | $16.97M derived: sum of 3 quarters · filed 2020-02-28 | $21.22M 10-K · filed 2020-02-28 |
| 2017-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $9.06M derived: sum of 2 quarters · filed 2018-11-09 | $13.31M 10-Q · filed 2018-11-09 | $13.90M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $7.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $11.67M 10-Q · filed 2018-08-09 | $12.26M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2017-03-31 | $4.26M 10-Q · filed 2018-05-10 | $4.85M derived: sum of 2 quarters · filed 2019-03-01 | ||
| 2016-12-31 | $590.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$41.79M 10-K · filed 2019-03-01 | ||
| 2016-09-30 | -$42.38M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |